NDLI: Intermittent Hirudin Versus Continuous Heparin for Anticoagulation in Continuous Renal Replacement Therapy

Content Provider	Taylor & Francis Online
Author	Spies, Claudia Hein, Ortrud Vargas Siebert, Gerda Kox, Wofgang J. Neumayer, Hans H. Diehl, Thorsten Ronco, Claudio Morgera, Stanislao Heymann, Christian Von Ziemer, Sabine
Abstract	Background: Besides possible bleeding complications a further problem in anticoagulation during continuous renal replacement therapy (CRRT) is the development of heparin‐induced thrombocytopenia type II (HIT II) where further anticoagulation with heparin is contraindicated. The application of continuous hirudin as alternative for heparin caused bleeding complications by comparable filter efficacy. Aim of this prospective‐controlled pilot study was to compare the efficacy and safety of intermittent hirudin and continuous heparin for anticoagulation during CRRT in critically ill patients. Methods: 26 patients receiving CRRT were randomly allocated to two groups: Heparin group (14 patients): continuous administration of 250 IU/h heparin, dose was adjusted in 125 IU/h steps with a targeted activated clotting time (ACT) of 180–210 s. Hirudin group (12 patients): initial bolus application of 2–2–5 µg/kg hirudin, dose was adjusted in 2 µg/kg bolus steps with a targeted ecarin clotting time (ECT) > 80 s. Observation time was 96 hours. Results: Measured filter run time was virtually longer for heparin. No bleeding complications were observed in the hirudin group, two bleeding complications in the heparin group. Conclusions: Intermittent hirudin can be used safely for anticoagulation in CRRT. However, the in tendency better filter survival for heparin elucidates the need for further investigations to find the right dosage equilibrium between filter clotting and bleeding complications.
Starting Page	297
Ending Page	303
Page Count	7
File Format	PDF HTM / HTML
ISSN	0886022X 15256049
DOI	10.1081/JDI-120039529
Journal	Renal Failure
Volume Number	26
Issue Number	3
Language	English
Publisher	Taylor & Francis
Publisher Date	2009-07-07
Access Restriction	Open
Subject Keyword	Anticoagulation Bleeding Efficacy Hemofiltration Heparin Hirudin
Content Type	Text
Resource Type	Article
Subject	Critical Care and Intensive Care Medicine Nephrology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Heparin vs recombinant hirudin for anticoagulation in continuous renal replacement therapy

Iloprost for Additional Anticoagulation in Continuous Renal Replacement Therapy—A Pilot Study

Heparin vs recombinant hirudin for anticoagulation in continuous renal replacement therapy

A NOVEL METHOD FOR REGIONAL CITRATE ANTICOAGULATION IN CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVHF)

Heparin vs recombinant hirudin for anticoagulation in continuous renal replacement therapy

Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate?

Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial

Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial

Revised algorithm for heparin anticoagulation during continuous renal replacement therapy

Intermittent Hirudin Versus Continuous Heparin for Anticoagulation in Continuous Renal Replacement Therapy

Similar Documents

Heparin vs recombinant hirudin for anticoagulation in continuous renal replacement therapy

Iloprost for Additional Anticoagulation in Continuous Renal Replacement Therapy—A Pilot Study

Heparin vs recombinant hirudin for anticoagulation in continuous renal replacement therapy

A NOVEL METHOD FOR REGIONAL CITRATE ANTICOAGULATION IN CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVHF)

Heparin vs recombinant hirudin for anticoagulation in continuous renal replacement therapy

Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate?

Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial

Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial

Revised algorithm for heparin anticoagulation during continuous renal replacement therapy

Intermittent Hirudin Versus Continuous Heparin for Anticoagulation in Continuous Renal Replacement Therapy